Your email has been successfully added to our mailing list.

×
0 0 0 0.0384615384615385 0.0576923076923077 0.0384615384615385 0.0480769230769231 0.115384615384615
Stock impact report

Examining What Is Next For Arch Therapeutics [Seeking Alpha]

Arch Therapeutics, Inc. (ARTH) 
NASDAQ:AMEX Investor Relations: ir.archtherapeutics.com
Company Research Source: Seeking Alpha
Examining What Is Next For Arch Therapeutics Summary Arch now has their first FDA approval. The company expects the review process for the CE Mark to be completed this fall. The stock is about the same price as it was four years ago. On June 26, 2015, I published an article on SeekingAlpha introducing Arch Therapeutics: “ The Cheapest Medical Device Stock I've Ever Seen Arch had a strong patent position and a very important advantage: Their product, AC5, is regulated as a device, not a drug. That offered a faster, lower-cost path to approval. So what's happened since mid-2015? Lots. For less than $37 million, Arch was able to take AC5 from an idea to FDA approval on December 17, 2018. But the company had to pivot to approval for external use in wound care for problems like pressure ulcers (bedsores), diabetic foot ulcers, and burns. Around the end of this year, they will file an IND (Investigational New Device) application with the FDA for approval of a clinical trial for internal use Show less Read more
Impact Snapshot
Event Time:
ARTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ARTH alerts
Opt-in for
ARTH alerts

from News Quantified
Opt-in for
ARTH alerts

from News Quantified